PROCEPT BioRobotics will report Q3 2025 financial results on November 4, with a conference call at 4:30 PM ET.
Quiver AI Summary
PROCEPT BioRobotics Corporation has announced it will release its financial results for the third quarter of 2025 on November 4, 2025, after market close. Following the announcement, management will host a conference call at 4:30 p.m. Eastern Time, which investors can access via a webcast link or by registering for a dial-in option. The company is focused on improving patient care in urology, particularly in the treatment of benign prostatic hyperplasia (BPH), leveraging its AQUABEAM and HYDROS robotic systems. These systems provide effective, safe outcomes for men with lower urinary tract symptoms, supported by extensive clinical evidence. An archive of the conference call will be available on the Company’s website for at least 90 days.
Potential Positives
- PROCEPT BioRobotics is set to announce its financial results for Q3 2025 on November 4, 2025, which could provide important insights into the company's performance and growth potential.
- The upcoming conference call allows investors to engage directly with management, fostering transparency and communication between the company and its stakeholders.
- The mention of over 150 peer-reviewed publications supporting Aquablation therapy enhances the credibility and recognition of the company’s innovative solutions in treating BPH.
- PROCEPT BioRobotics emphasizes its unique technology with the HYDROS Robotic System, highlighting its potential to transform BPH treatment, which addresses a significant health issue affecting millions of men in the U.S.
Potential Negatives
- Announcement of financial results may indicate a potential concern about the company's performance, prompting scrutiny from investors.
- The timing of the financial report after market close could suggest that the company is preparing for potentially disappointing news or results.
FAQ
When will PROCEPT BioRobotics announce its Q3 2025 financial results?
PROCEPT BioRobotics will report its financial results for Q3 2025 after market close on November 4, 2025.
How can I listen to the PROCEPT BioRobotics conference call?
Investors can listen to the conference call via the webcast link or by registering for the dial-in option for analysts.
Where can I find the archived recording of the conference call?
The archived recording will be available in the “Investors” section of PROCEPT BioRobotics' website for at least 90 days.
What is Aquablation therapy offered by PROCEPT BioRobotics?
Aquablation therapy is a robotic solution designed for effective BPH treatment, independent of prostate size or surgeon experience.
How many clinical publications support Aquablation therapy?
There are over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRCT Insider Trading Activity
$PRCT insiders have traded $PRCT stock on the open market 22 times in the past 6 months. Of those trades, 1 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $PRCT stock by insiders over the last 6 months:
- ANTAL ROHIT DESAI has made 0 purchases and 21 sales selling 150,000 shares for an estimated $9,381,353.
- FREDERIC H MOLL purchased 20,000 shares for an estimated $785,138
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PRCT Hedge Fund Activity
We have seen 147 institutional investors add shares of $PRCT stock to their portfolio, and 126 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WESTFIELD CAPITAL MANAGEMENT CO LP added 849,792 shares (+113.5%) to their portfolio in Q2 2025, for an estimated $48,948,019
- MACKENZIE FINANCIAL CORP added 708,656 shares (+inf%) to their portfolio in Q2 2025, for an estimated $40,818,585
- BAILLIE GIFFORD & CO added 562,479 shares (+179.2%) to their portfolio in Q2 2025, for an estimated $32,398,790
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 440,702 shares (+128.3%) to their portfolio in Q2 2025, for an estimated $25,384,435
- FMR LLC removed 423,035 shares (-5.1%) from their portfolio in Q2 2025, for an estimated $24,366,816
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC removed 410,292 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $23,632,819
- CHAMPLAIN INVESTMENT PARTNERS, LLC added 394,450 shares (+58.3%) to their portfolio in Q2 2025, for an estimated $22,720,320
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PRCT Analyst Ratings
Wall Street analysts have issued reports on $PRCT in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 09/02/2025
- Piper Sandler issued a "Overweight" rating on 08/07/2025
- Wells Fargo issued a "Overweight" rating on 08/07/2025
- Morgan Stanley issued a "Overweight" rating on 07/15/2025
- B of A Securities issued a "Buy" rating on 04/25/2025
To track analyst ratings and price targets for $PRCT, check out Quiver Quantitative's $PRCT forecast page.
$PRCT Price Targets
Multiple analysts have issued price targets for $PRCT recently. We have seen 6 analysts offer price targets for $PRCT in the last 6 months, with a median target of $59.0.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $50.0 on 10/15/2025
- Suraj Kalia from Oppenheimer set a target price of $60.0 on 09/02/2025
- Matt O'Brien from Piper Sandler set a target price of $55.0 on 08/07/2025
- Nathan Treybeck from Wells Fargo set a target price of $58.0 on 08/07/2025
- Patrick Wood from Morgan Stanley set a target price of $68.0 on 07/15/2025
- Craig Bijou from B of A Securities set a target price of $84.0 on 04/25/2025
Full Release
SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by following one of the below links:
- Webcast link for interested listeners :
- Dial-in registration for sell-side research analysts:
Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com .
An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com . Each webcast will be available for replay for at least 90 days after the event.
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM
®
and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
[email protected]
